Efficacy of neuroprotective treatment including pyrimidine nucleotides in secondary uveitic glaucoma
Journal Title: Офтальмологический журнал - Year 2018, Vol 0, Issue 2
Abstract
Background: Secondary glaucoma is found in 18% to 38% of patients with uveitis, and is one of the most severe uveitic complications. The glaucomatous process is characterized by the progressive optic nerve neuropathy. The lack of efficacy of conventional neuroprotective approaches urged us to search for novel medications capable of stabilizing glaucoma. Purpose: To investigate the efficacy of neuroprotective treatment with pyrimidine nucleotides for secondary uveitic glaucoma. Materials and Methods: Patients with secondary uveitic glaucoma were divided into the study group (23 patients; 23 eyes) and the control group (21 patients; 21 eyes). The multicomponent neuroprotective treatment of the study group (but not of the control group) included a direct neuroprotector, Nucleo CMP Forte® drug containing two pyrimidine nucleotides, cytidine 5'-monophosphate and uridine 5'- triphosphate. The group received 2 ml of the drug intramuscularly daily for 10 days, and, thereafter, 2 capsules orally twice daily for 20 days. Each patient underwent visual acuity measurement and perimetry. In addition, phosphene threshold current (PTC) and critical frequency of phosphene (CFP) were determined. Results: Although no improvements in functional characteristics of the visual system were observed in the control group, the use of the pyrimidine nucleotide-containing drug as a component of therapy for uveitic glaucoma contributed to a 39% improvement in visual acuity, 17% increase in total visual field, 22% decrease in PTC, and 23% increase in CFP compared with baseline. Our long-term findings evidence that glaucoma was stabilized with neuroprotective therapy including, in particular, Nucleo CMP Forte, with generally maintained peripapillary RNFL thickness. Conclusion: The use of the pyrimidine nucleotide-containing drug as a component of therapy for uveitic glaucoma promoted an improvement in visual function and contributed to stabilization of glaucoma over 6-8 months
Authors and Affiliations
V. Savko Snr
Keywords
Related Articles
- EP ID EP422113
- DOI 10.31288/oftalmolzh/2018/2/2933
- Views 110
- Downloads 0
Examination of school children’s threshold exposure duration for recognition of test objects (TEDRTO) for assessment of their visual fatigue
Background: Due to increased visual load during schooling, it is important to use a methodology for assessment of visual fatigue in children which would be understandable to them and which would not require much time. P...
Retinal structural changes in patients with Alzheimer's disease
Background: Retinal disorders in patients with Alzheimer's disease (AD) are given special attention. Purpose: To identify optical coherence tomography (OCT)-based retinal structural changes in patients with mild or mode...
Accidental intralenticular injection of dexametasone intravitreal implant during the treatment of refractory diabetic macular oedema
This article deals with the clinical case of accidental intralenticular injection of dexamethasone implant during the treatment of refractory diabetic macula oedema. The paper is based on a comprehensive research of simi...
Correlation between axial length and anterior chamber depth of the eye and retinal disorders in type 2 diabetic rabbits with myopia
Background. Recently, a protective effect of high myopia on the retina in diabetes has been reported; however, the mechanism of the interrelation between the elongation of axial length and the severity of diabetic compli...
Efficacy of 577-nm retinal pigment epithelium laser photocoagulation in age-related maculopathy patients with various extents of morphological and functional loss
Background: There is no unanimously adopted approach to titrating laser settings in subthreshold retinal laser photocoagulation (LPC) without ophthalmoscopically visible fundus changes. The efficacy of this approach to t...